Top25-SA-Banner

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Intra-Cellular Therapies (ITCI) and Dermira (DERM)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nektar Therapeutics (NKTR), Intra-Cellular Therapies (ITCI) and Dermira (DERM).

Nektar Therapeutics (NKTR)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Nektar Therapeutics, with a price target of $86. The company’s shares opened today at $38.04, close to its 52-week low of $30.30.

According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 3.5% and a 40.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.

Currently, the analyst consensus on Nektar Therapeutics is a Moderate Buy with an average price target of $78.67, which is a 106.8% upside from current levels. In a report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $103 price target.

.

See today’s analyst top recommended stocks >>

Intra-Cellular Therapies (ITCI)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Intra-Cellular Therapies today and set a price target of $28. The company’s shares opened today at $19.30.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 50.0% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intra-Cellular Therapies with a $30 average price target, implying a 55.4% upside from current levels. In a report issued on October 25, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $32 price target.

.

Dermira (DERM)

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Dermira, with a price target of $10. The company’s shares opened today at $12.62.

Rivkind Koffler commented:

“We reiterate our Neutral rating and $10 PT and want to observe new patient ramp, refills, and gross-to-net discounts for a few quarters before potentially getting more constructive.”

According to TipRanks.com, Koffler is a 4-star analyst with an average return of 8.7% and a 44.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Dermira is a Hold with an average price target of $15.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.